According to KBC Securities analysts, FB102 could become a best-selling drug and aligns with Argenx's long-term expansion plans.
Argenx aims to broaden its immunology footprint because its revenue has relied heavily on its leading drug, Vyvgart. Vyvgart is approved for multiple autoimmune conditions and still generates robust demand, helping Argenx deliver better-than-expected second-quarter earnings.
In a research note, analysts at Van Lanschot Kempen observed that the company is positioning itself for growth beyond the anticipated Vyvgart peak in the early 2030s, adding, "All in all, the right deal at the right time."
Through this deal, Argenx obtains an early-stage drug candidate that may compensate for the future downturn in Vyvgart revenue. Forte's FB102 targets distinct autoimmune pathways and has the potential to address large patient populations, which aligns with Argenx's strategy of building a diversified immunology franchise.
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
FB102 targets the IL-2 receptor pathway, which plays a key role in regulating immune responses. Vitiligo, an autoimmune condition causing skin depigmentation, affects roughly 1-2% of the global population, while celiac disease, triggered by gluten, impacts about 1% of people worldwide. These large patient pools make FB102 a potentially significant growth driver beyond the current Vyvgart franchise.
Vyvgart (efgartigimod), which accounts for nearly all of Argenx's revenue, has received approval for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and it has demonstrated potential in additional autoimmune conditions. The company reported better-than-expected earnings in the second quarter, but analysts anticipate a peak for Vyvgart in the early 2030s. By acquiring Forte, Argenx gains FB102, an early-stage antibody targeting IL-2 receptor signaling, which could address large patient populations in vitiligo and celiac disease, potentially expanding its pipeline beyond Vyvgart's lifecycle.
The deal also reflects Argenx's broader effort to reduce reliance on a single product. Vyvgart currently accounts for nearly all of the company's revenue, and while its market remains strong, the acquisition of FB102 offers a complementary mechanism of action that could serve different autoimmune conditions. Forte's asset is still in early development, meaning Argenx will shoulder clinical and regulatory risks, but the potential market for vitiligo and celiac disease - each affecting millions of patients worldwide - makes the bet worthwhile.
The IL-2 receptor pathway is a critical regulator of T-cell activity, and modulating it could offer a novel approach for treating autoimmune diseases that currently have limited options. Vitiligo and celiac disease, both with significant unmet need, represent substantial commercial opportunities for Argenx as it seeks to diversify its revenue stream beyond Vyvgart's expected peak.
On Monday, Argenx stock dropped up to 0.9% before recovering, while Forte shares surged as high as 42% to $77.86 in premarket activity.
Argenx was advised by Goldman Sachs International and Freshfields LLP, while Forte retained Guggenheim Securities LLC for financial advice and Wilson Sonsini Goodrich & Rosati for legal counsel.
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
